Literature DB >> 4435959

Type-specific opsonic antibodies in streptococcal pyoderma.

A L Bisno, K E Nelson.   

Abstract

Prospective studies of streptococcal pyoderma were carried out among black children enrolled in Project Headstart centers in Holmes County, Miss. Sera collected from 28 of these children in early October were tested for opsonic antibodies to one of two prevalent skin strains of group A streptococci isolated from them on one or more occasions over the preceding 3 months. The two streptococcal strains (A and B) belong to M-types previously unrecognized. Ten subjects (36%) had antibody to their homologous serotypes detectable by the indirect bactericidal test: this included 6 of 10 subjects infected with strain B but only 4 of 18 infected with strain A (P < 0.05). Of 17 children who had strains A or B isolated from skin lesions only, 12% developed type-specific antibodies (TSA) against the infecting serotype. In contrast, 11 subjects had these strains isolated from throat cultures (either with or without associated pyoderma), and 72% had detectable TSA (P < 0.01). There was no demonstrable relationship between the development of antibodies to streptococcal extracellular products or to non-type-specific cellular antigens and the development of TSA. These results demonstrate that type-specific immune responses do occur following infection with pyoderma streptococci. The frequency with which such antibodies develop is variable and appears related to a number of factors, including the immunologic properties of the infecting strain and the site of bacterial colonization. Pharyngeal carriage may represent an important mechanism for development of acquired immunity to skin strains of group A streptococci.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4435959      PMCID: PMC423111          DOI: 10.1128/iai.10.6.1356-1361.1974

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  Type-specific streptococcal antibody.

Authors:  F W DENNY; W D PERRY; L W WANNAMAKER
Journal:  J Clin Invest       Date:  1957-07       Impact factor: 14.808

2.  Streptococcal bacteriostatic antibody in patients treated with penicillin.

Authors:  G DAIKOS; L WEINSTEIN
Journal:  Proc Soc Exp Biol Med       Date:  1951-10

3.  Cross-reacting and monotypic T antigens of nephritogenic pyoderma streptococci: the type 56 system.

Authors:  A L Bisno; M Svartman; G H Stollerman
Journal:  J Immunol       Date:  1971-06       Impact factor: 5.422

4.  Studies of antibodies to non-type-specific antigens associated with streptococcal M protein in the sera of patients with rheumatic fever.

Authors:  E H Beachey; I Ofek; A L Bismo
Journal:  J Immunol       Date:  1973-11       Impact factor: 5.422

5.  Factors influencing serum antibody responses in streptococcal pyoderma.

Authors:  A L Bisno; K E Nelson; P Waytz; J Brunt
Journal:  J Lab Clin Med       Date:  1973-03

6.  Type-specific streptococcal antibodies in pyodermal nephritis.

Authors:  S Bergner-Rabinowitz; I Ofek; M A Davies; K Rabinowitz
Journal:  J Infect Dis       Date:  1971-11       Impact factor: 5.226

7.  Cutaneous streptococcal infections in Vietnam.

Authors:  A M Allen; D Taplin; L Twigg
Journal:  Arch Dermatol       Date:  1971-09

8.  Peptic digestion of streptococcal M protein. I. Effect of digestion at suboptimal pH upon the biological and immunochemical properties of purified M protein extracts.

Authors:  M W Cunningham; E H Beachey
Journal:  Infect Immun       Date:  1974-02       Impact factor: 3.441

9.  Persistence of type-specific antibodies in man following infection with group A streptococci.

Authors:  R C LANCEFIELD
Journal:  J Exp Med       Date:  1959-08-01       Impact factor: 14.307

10.  Accessory plasma factors involved in the bactericidal test for type-specific antibody to group A streptococci. I. A typical behavior of some human and rabbit bloods.

Authors:  G H STOLLERMAN; F S KANTOR; B D GORDON
Journal:  J Exp Med       Date:  1958-10-01       Impact factor: 14.307

View more
  8 in total

1.  Immunogenic and Genetic Factors in Rheumatic Fever.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

Review 2.  Acute rheumatic fever and streptococci: the quintessential pathogenic trigger of autoimmunity.

Authors:  Soumya D Chakravarty; John B Zabriskie; Allan Gibofsky
Journal:  Clin Rheumatol       Date:  2014-06-04       Impact factor: 2.980

3.  A large outbreak of streptococcal pyoderma in a military training establishment.

Authors:  J G Cruickshank; N F Lightfoot; K H Sugars; G Colman; M D Simmons; J Tolliday; E H Oakley
Journal:  J Hyg (Lond)       Date:  1982-08

4.  Skin sepsis in meat handlers: observations on the causes of injury with special reference to bone.

Authors:  M Barnham; J Kerby
Journal:  J Hyg (Lond)       Date:  1981-12

5.  Murine model of recurrent group G streptococcal cellulitis: no evidence of protective immunity.

Authors:  A L Bisno; J M Gaviria
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

6.  Streptococcal Immunity Is Constrained by Lack of Immunological Memory following a Single Episode of Pyoderma.

Authors:  Manisha Pandey; Victoria Ozberk; Ainslie Calcutt; Emma Langshaw; Jessica Powell; Tania Rivera-Hernandez; Mei-Fong Ho; Zachary Philips; Michael R Batzloff; Michael F Good
Journal:  PLoS Pathog       Date:  2016-12-27       Impact factor: 6.823

7.  High burden of impetigo and scabies in a tropical country.

Authors:  Andrew C Steer; Adam W J Jenney; Joseph Kado; Michael R Batzloff; Sophie La Vincente; Lepani Waqatakirewa; E Kim Mulholland; Jonathan R Carapetis
Journal:  PLoS Negl Trop Dis       Date:  2009-06-23

8.  Immune Cross-Opsonization Within emm Clusters Following Group A Streptococcus Skin Infection: Broadening the Scope of Type-Specific Immunity.

Authors:  Hannah R Frost; Delphine Laho; Martina L Sanderson-Smith; Paul Licciardi; Susan Donath; Nigel Curtis; Joseph Kado; James B Dale; Andrew C Steer; Pierre R Smeesters
Journal:  Clin Infect Dis       Date:  2017-10-16       Impact factor: 9.079

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.